NewsRoom Articles - Page 38 of 144 - PsychedelicNewsWire (PNW)

FridaySep 23, 2022 11:15 am

Researchers Investigate Whether Psilocybin Mushrooms Can Help Combat Obesity

Psilocybin is the primary active compound found in hallucinogenic mushrooms. This compound usually turns into psilocin upon consumption. Recent research has provided evidence showing that psilocybin-assisted therapy may be effective in treating addiction, which has led others to wonder whether the psychedelic could also help individuals to control food cravings. A 2021 study also found that individuals who had ingested a classic psychedelic at least once in their lives had a considerably lower chance of being obese or overweight. These findings prompted a group of investigators to begin conducting research on whether psilocybin could help treat eating disorders and obesity.…

ThursdaySep 22, 2022 12:45 pm

Trial Clinic for Psychedelics to Open in London

After decades of prohibition and criminalization, various jurisdictions around the world have begun to loosen their restrictive psychedelic policies in what has been dubbed the psychedelics renaissance. There has been a significant surge in psychedelic interest among the scientific community, with researchers running several studies to look into the potential benefits and risks of using hallucinogenic drugs medicinally. Research has already shown that psychedelics have plenty of promise as treatments for mental-health conditions such as PTSD, depression and eating disorders, especially when paired with psychotherapy. Researchers in London have been conducting clinical trials to test the potential of psychedelics as…

WednesdaySep 21, 2022 3:58 pm

Native American Church Appeals to Congress to Fund Preservation, Cultivation of Peyote

Last week, leaders of the Native American Church (NAC) asked Congress to allocate funds toward efforts to preserve lands where peyote can be cultivated. Peyote is a psychedelic cacti that is often used in religious ceremonies of the Native American Church. The plant’s primary habitat is located in Texas, near the United States-Mexico border. The federally protected plant is classified as a Schedule I substance but can be cultivated, harvested and used by the church, per an amendment to the American Indian Religious Freedom Act. Despite federal protections, the plant’s supply is limited, which is why members of this particular…

TuesdaySep 20, 2022 12:57 pm

Hamilton Morris Confirmed as Keynote Speaker at Convergence Psychedelic Conference

Convergence, the biggest psychedelic culture and business conference in California, recently announced that Hamilton Morris would be a keynote speaker at the conference. Morris is a well-known advocate in the psychedelics space. In addition to being a scientific researcher, a journalist and a filmmaker, he has a television show known as “Hamilton’s Pharmacopeia.” The show, which runs on Vice TV, allows him to bring life to stories and experiences of psychedelics along with the uses of these substances and their cultural significance and the chemistry behind them. At the moment, Morris is a consultant at Compass Pathway’s Discover Center, which…

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants…

MondaySep 19, 2022 10:58 am

An Overview of San Francisco’s Psychedelics Decriminalization Measure

Last week, the city of San Francisco decriminalized entheogenic substances after its Board of Supervisors unanimously passed a measure that made entheogens the lowest priority for city law enforcement. The measure was sponsored by Supervisors Hillary Ronen and Dean Preston. Its approval is a victory for Decriminalize Nature’s San Francisco chapter. Decriminalize Nature has influenced similar measures in Detroit, Oakland, Seattle, Denver and Washington, DC, as well as other counties and cities in the country. The city’s initiative references SB 519, a California bill forwarded by Sen. Scott Wiener. This bill called for the decriminalization of a range of psychedelics,…

FridaySep 16, 2022 2:29 pm

San Francisco Passes Resolution to Decriminalize Psilocybin Mushrooms

Last week, San Francisco became the latest and largest city in America to decriminalize psychedelics, including psilocybin mushrooms and ayahuasca. This move to decriminalize comes as a Senate bill from the state of California, which called for the decriminalization of psilocybin mushrooms, DMT, MDMA, LSD and ibogaine, was put on ice until 2023. During a meeting held last week, San Francisco’s Board of Supervisors unanimously approved a resolution that would make arresting individuals for the use, cultivation and distribution of federally banned psychedelics the lowest enforcement priority for law enforcement in the county. The resolution was introduced and sponsored by…

ThursdaySep 15, 2022 12:17 pm

Study Suggests Reported Psychedelics Microdosing Effects Are Due to User Expectancy

Microdosing is the practice of consuming low doses of hallucinogenic psychedelics such as LSD and psilocybin. This practice appears to be growing in popularity, with individuals who microdose touting the practice’s potential mental health benefits. These supposed benefits include improvements in cognitive function, concentration, mood and creativity. Now new experimental research suggests that the benefits of psilocybin microdosing may be brought on by users’ expectations. Psilocybin is the primary active ingredient found in hallucinogenic mushrooms. This research was led by Federico Cavanna, who together with colleagues, tested psilocybin’s microdosing effects. For their study, the investigators recruited 34 participants, including 11…

WednesdaySep 14, 2022 12:05 pm

Congressman Says Lawmakers’ Reluctance Regarding Psychedelic Therapy Is Embarrassing

As the decriminalization movement spreads in more local municipalities and states, the conversation around psychedelics reform continues to gain footing. On a federal level, one congressman is trying to gain more legislators’ to support therapeutic access to psychedelic substances, which he believes may be a game changer. Rep. Jared Huffman is one of the House members who voted to pass an amendment that would lift research barriers imposed on psychedelics. The amendment, which was proposed by Rep. Alexandria Ocasio-Cortez in 2019, was ultimately rejected. In 2021, the amendment was again reintroduced but failed to be approved. Despite this, the House…

TuesdaySep 13, 2022 2:14 pm

Georgia Legislators Discuss Psychedelics for Veterans During Committee Hearing

Hallucinogenic drugs have seen a major resurgence in scientific interest over the past decade. Psychedelics were extremely popular from the mid-1960s to the mid-1970s before they were criminalized. Even though people still consumed psychedelic drugs, albeit illegally, researchers were basically unable to study them for their potential benefits and risks. But with psychedelic interest among the scientific community surging, it has became clear that psychedelic drugs do have medical applications. Clinical trials have found that hallucinogenic drugs have the potential to treat mental health conditions such as anxiety disorders, as well as eating disorders, when paired with conventional psychotherapy. Researchers…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050